Fasciola hepatica antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Fasciola hepatica antibodies pairs and antigen for animal health (animal Bovines/Cattle, Ovines/Sheep infectious disease Fascioliasis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Ruminants disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P074-Ag01	Recombinant Fasciola hepatica protein	$3090.00
GMP-VT-P074-Ab01	Anti-Fasciola hepatica mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P074-Ab02	Anti-Fasciola hepatica mouse monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P074-Ag01
Product Name	Recombinant Fasciola hepatica protein
Pathogen	Fasciola hepatica
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Fasciola hepatica antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Fasciola hepatica level test of animal Bovines/Cattle, Ovines/Sheep infectious disease with Fascioliasis.
Tag	His
Product description	Recombinant Fasciola hepatica proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P074-Ab01,GMP-VT-P074-Ab02
Pathogen	Fasciola hepatica
Product Name	Anti-Fasciola hepatica mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Fasciola hepatica antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Fasciola hepatica antibodies in Fasciola hepatica level test of animal Bovines/Cattle, Ovines/Sheep infectious disease with Fascioliasis.
Product description	Anti-Fasciola hepatica mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Fasciola hepatica antibodies./td>
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen

Fasciola hepatica is a trematode or flatworm species that belongs to the class Trematoda and the phylum Platyhelminthes. This species is commonly referred to as the sheep liver fluke or common liver fluke due to its propensity for infecting the liver of various mammalian hosts, including humans.

The adult Fasciola hepatica worm measures approximately 25 mm in length and 10 mm in width. The life cycle of this parasite starts when eggs are excreted in the feces of infected hosts and deposited in freshwater. In these environments, the eggs hatch into miracidia and subsequently develop into sporocysts and rediae, which are intermediate hosts. These intermediate hosts release cercariae, which are free-living and capable of penetrating the skin of the definitive host, which can be sheep, cattle, or humans.

Once inside the definitive host, the cercariae transform into metacercariae, which then migrate to the liver via the hepatic portal vein. The young flukes penetrate the liver capsule and migrate through the liver parenchyma before they reach their final destination in the bile ducts, where they mature into adults and start laying eggs.

While Fasciola hepatica primarily targets sheep and cattle, human cases are not uncommon, especially in developing countries with poor sanitation and hygiene practices. Fascioliasis, the disease caused by Fasciola hepatica infection, can present as an acute or chronic condition in humans. The acute form of the disease is characterized by symptoms such as fever, abdominal pain, nausea, vomiting, and diarrhea, while chronic cases can lead to biliary duct obstruction, jaundice, cholangitis, and liver cirrhosis.

To diagnose Fasciola hepatica infection, healthcare providers utilize a range of techniques, including imaging studies, blood tests, and stool examinations. Imaging studies such as ultrasound, CT scans, and MRI can reveal the presence of liver lesions and biliary duct dilation, while blood tests such as ELISA identify host antibodies against Fasciola hepatica antigens. Stool examinations are also used to detect Fasciola hepatica eggs or parasite antigens found in the feces.

A better understanding of the Fasciola hepatica genome and proteome would allow for the development of more effective diagnostic methods and treatment options. Recent studies have started to shed light on the molecular mechanisms underlying host-parasite interactions in Fasciola hepatica infections. For instance, proteomics analyses have identified numerous proteins involved in immune evasion, including cathepsin L protease and excretory-secretory antigen (ES), which are released by the parasite to avoid detection and destruction by the host's immune system.

In conclusion, Fasciola hepatica is a parasitic flatworm with significant impacts on human and animal health. It primarily infects the liver and biliary tract, leading to fascioliasis, a condition that can present as either acute or chronic disease. Healthcare providers utilize various diagnostic methods to detect Fasciola hepatica infection, including imaging studies, blood tests, and stool examinations. Further research into the molecular mechanisms of Fasciola hepatica infections could offer new insights into disease prevention and treatment strategies.

About GDU